Skip to content

Author

H. I. Umar

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Nov 2026

In silico drug repurposing to identify activators targeting SLC7A11/xCT for cardiotoxicity: Molecular docking, dynamics simulation, and ADMET analysis

Results suggest that dexamethasone and prulifloxacin are promising candidates for repurposing as cardioprotective agents, offering potential therapeutic options for mitigating drug-induced cardiotoxicity.

M. M. Alshehri, Nemat Ali, M. Alharbi et al. · 0 citations
Oct 2026

Finding Novel Inhibitors of FMS-like Tyrosine Kinase 3 from Selected FDA-approved Anticancer Drugs: Insights from Molecular Docking, MD Simulations, and ADMET Profiling.

BACKGROUND Wild-type FLT3 (WT-FLT3) has emerged as a relevant molecular target in Acute Myeloid Leukemia (AML), with increasing evidence implicating its role in leukemic proliferation and resistance, even in the absence of FLT3 mutations. Although gilteritinib is an approved FLT3 inhibitor, its efficacy in WT-FLT3 AML...

Mohammed H. al Mughram, L. J. Babatola, Md. Nazim Uddin et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.